Digital newsroom

June 16, 2020

Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Cancer Patients

May 29, 2020

Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020

May 14, 2020

New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results

May 5, 2020

New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates for Comparing Colorectal Cancer Screening Methods

April 2, 2020

EXACT SCIENCES HIGHLIGHTS THE OPPORTUNITY TO SEEK SCREENING WITH COLOGUARD® THROUGH TELEHEALTH

March 15, 2020

Message from Chairman & CEO, Kevin Conroy

March 11, 2020

FIGHT COLORECTAL CANCER RECEIVES GRANT FROM EXACT SCIENCES TO LAUNCH PROGRAM AIMED AT REDUCING PATIENT BARRIERS TO COLORECTAL CANCER SCREENING

December 12, 2019

New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-Negative or Node-Positive Early-Stage Breast Cancer

December 5, 2019

Dr. David Ahlquist, Co-Inventor of Cologuard, Named a Fellow of the National Academy of Inventors

November 8, 2019

Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company

November 8, 2019

Exact Sciences Presents Data on Blood-based Test for Detection of Hepatocellular Carcinoma, Earns FDA Breakthrough Device Designation

October 29, 2019

Exact Sciences Presents New Stool-based Colorectal Cancer Screening Performance Data, Initiates Prospective Screening Study

1 2 3 4 5 6 7 8 9

Multimedia

Videos Photos